# Kura Oncology (KURA) — Earnings

KURA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/kura/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.77 |
| EPS estimate | −$0.88 |
| EPS surprise | +12.23% |
| Revenue surprise | +3.53% |
| Revenue | $20.9M |
| Revenue estimate | $20.2M |
| Reported | Aug 12, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1422143/000119312526346884/kura-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/f003c03c-05ac-59b0-a3b8-33a09a0053ef.html) |

Kura Oncology reported Q2 2026 results on August 12, 2026. It posted a loss of $0.77 per share, narrower than the $0.88 loss expected, a 12.23% beat. Revenue was $20.9 million, about 3% above the $20.2 million estimate. Compared with Q2 2025, the loss was slightly wider than $0.75, while revenue rose about 37% from $15.3 million.

Every quarter in the table is a loss. The annual loss was $2.03 per share in 2022, $2.08 in 2023 and $2.03 in 2024, then widened to $3.18 in 2025. The first half of 2026 shows a $1.60 loss, against $1.41 in the first half of 2025. The largest quarterly loss here was $0.92 in Q4 2025. Revenue figures start only in Q4 2024, at $53.9 million, the highest in the table; since then quarterly revenue has ranged from $14.1 million to $20.9 million. Over the last 20 quarters, Kura beat the EPS estimate 13 times and missed 7 times.

Kura reported Q3 between November 2 and November 7 in each of the past five years. That points to early November 2026 for the next report. It will show how revenue and the quarterly loss compare with recent periods.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 12, 2026 | −$0.88 | −$0.77 | 12.23% | $20.2M | $20.9M |
| Q1 2026 | May 12, 2026 | −$0.83 | −$0.83 | 0.54% | $26.0M | $18.3M |
| Q4 2025 | Mar 5, 2026 | −$0.64 | −$0.92 | -43.97% | $35.4M | $17.3M |
| Q3 2025 | Nov 4, 2025 | −$0.73 | −$0.85 | -16.44% | $18.9M | $20.8M |
| Q2 2025 | Aug 7, 2025 | −$0.37 | −$0.75 | -104.97% | $42.7M | $15.3M |
| Q1 2025 | May 1, 2025 | −$0.60 | −$0.66 | -10.02% | $17.5M | $14.1M |
| Q4 2024 | Feb 26, 2025 | −$0.64 | −$0.22 | 65.39% | $53.8M | $53.9M |
| Q3 2024 | Nov 7, 2024 | −$0.63 | −$0.63 | -0.62% | — | — |
| Q2 2024 | Aug 8, 2024 | −$0.63 | −$0.59 | 5.77% | — | — |
| Q1 2024 | May 2, 2024 | −$0.55 | −$0.59 | -7.84% | — | — |
| Q4 2023 | Feb 27, 2024 | −$0.55 | −$0.55 | 0.15% | — | — |
| Q3 2023 | Nov 2, 2023 | −$0.54 | −$0.50 | 7.44% | — | — |
| Q2 2023 | Aug 3, 2023 | −$0.54 | −$0.53 | 2.61% | — | — |
| Q1 2023 | May 10, 2023 | −$0.54 | −$0.50 | 7.05% | — | — |
| Q4 2022 | Feb 23, 2023 | −$0.57 | −$0.49 | 14.34% | — | — |
| Q3 2022 | Nov 3, 2022 | −$0.56 | −$0.53 | 5.73% | — | — |
| Q2 2022 | Aug 3, 2022 | −$0.52 | −$0.52 | -0.85% | — | — |
| Q1 2022 | May 4, 2022 | −$0.52 | −$0.49 | 5.19% | — | — |
| Q4 2021 | Feb 24, 2022 | −$0.54 | −$0.49 | 8.41% | — | — |
| Q3 2021 | Nov 4, 2021 | −$0.54 | −$0.50 | 7.17% | — | — |

## Frequently Asked Questions

### When did Kura Oncology (KURA) last report earnings?

Kura Oncology last reported on Aug 12, 2026, covering fiscal Q2 2026.

### Did KURA beat earnings estimates?

Yes. Kura Oncology reported EPS of −$0.77 for Q2 2026 against a −$0.88 estimate — a 12.23% beat.

### How much revenue did KURA report last quarter?

Kura Oncology reported $20.9M in revenue for Q2 2026, against a consensus estimate of $20.2M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).